Apolipoprotein E2 (Arg136 → Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia

Journal of Lipid Research

Volumn 39, Issue 3, 1998, Pages 658-669

  März, Winfried ^a   Hoffmann, Michael M ^a   Scharnagl, Hubert ^a   Fisher, Eva ^b   Chen, Minchun ^c   Nauck, Markus ^a   Feussner, Giso ^d   Wieland, Heinrich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apolipoprotein B; Dysbetalipoproteinemia; Hep aran sulfate proteoglycans; Hypercholesterolemia; Hypertriglyceridemia; Low density lipoprotein receptor; Very low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E2; HEPARAN SULFATE; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEOGLYCAN; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN E; ARGININE; CYSTEINE;

ADULT; ARTICLE; CASE REPORT; DNA SEQUENCE; DYSLIPOPROTEINEMIA; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTRIGLYCERIDEMIA; MALE; PEDIGREE ANALYSIS; PRIORITY JOURNAL; RECEPTOR BINDING; AMINO ACID SEQUENCE; BLOOD; CELL CULTURE; CHEMISTRY; FIBROBLAST; GENETICS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE 3; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AMINO ACID SEQUENCE; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; ARGININE; BASE SEQUENCE; CELLS, CULTURED; CYSTEINE; FEMALE; FIBROBLASTS; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERLIPOPROTEINEMIA TYPE III; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, LDL;

EID: 0031594336     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240: 622-630.
2. Davignon, J., R. E. Gregg, and C. F. Sing. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8: 1-21.
3. Kowal, R. C., J. Herz, J. L. Goldstein, V. Esser, and M. S. Brown. 1989. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86: 5810-5814.
4. Takahashi, S., Y. Kawarabayasi, T. Nakai, J. Sakai, and T. Yamamoto. 1992. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. USA. 89: 9252-9256.
5. Kirn, D. H., H. Iijma, K. Goto, J. Sakai, H. Ishii, H. J. Kim, H. Suzuki, H. Kondo, S. Saeki, and T. Yamamoto. 1996. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271: 8373-8380.
6. Yamazaki, H., H. Bujo, J. Kusonoki, K. Seimiya, T. Kanaki, N. Morisaki, W. J. Schneider, and Y. Saito. 1996. Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member. J. Biol. Chem. 271: 24761-24768.
7. Weisgraber, K. H., S. C. Rall, Jr., and R. W. Mahley. 1981. Human E apoprotein heterogeneity. Cysteine arginine interchanges in the amino acid sequence of the apoE isoforms. J. Biol. Chem. 256: 9077-9083.
8. Corder, E. H., A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. E. Haines, and M. A. Pericak-Vance. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261: 921-923.
9. Ohm, T. G., M. Kirca, J. Bohl, H. Scharnagl, W. Gross, and W. März. 1995. ApoE influences not only cerebral senile plaque load, but also Alzheimer-type neurofibrillary tangles. Neuroscience. 66: 583-587.
10. Schneider, W. J., P. T. Kovanen, M. S. Brown, J. E. Goldstein, G. Utermann, W. Weber, R. J. Havel, E. Kotite, J. P. Kane, T. E. Innerarity, and R. W. Mahley. 1981. Familial dysbetalipoproteinemia. Abnormal binding of minant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenals of rats, rabbits and cows. J. Clin. Invest. 68: 1075-1085.
11. Lalazar, A., K. H. Weisgraber, S. C. Rall, Jr., H. Giladi, T. L. Innerarity, A. Z. Levanon, J. K. Boyles, B. Amit, M. Gorecki, R. W. Mahley, and T. Vogel. 1988. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J. Biol. Chem. 263: 3542-3545.
12. Utermann, G., M. Hees, and A. Steinmetz. 1977. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature. 269: 604-607.
13. Wilson, C., M. R. Wardell, K. H. Weisgraber, R. W. Mahley, and D. A. Agard. 1991. Three-dimensional structure of the LDL-receptor binding domain of human apolipoprotein E. Science. 252: 1817-1822.
14. Wilson, C., T. Mau, K. H. Weisgraber, M. R. Wardell, R. W. Mahley, and D. A. Agard. 1994. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure. 2: 713-718.
15. Wardell, M. R., K. H. Weisgraber, L. M. Havekes, and S. C. Rall, Jr. 1989. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J. Biol. Chem. 264: 21205-21210.
16. de Knijff, P., A. M. van den Maagdenberg, A. F. Stalenhoef, J. A. Leuven, P. N. Demacker, E. P. Kuyt, R. R. Frants, and E. M. Havekes. 1991. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Eeiden in an extended multigeneration pedigree. J. Clin. Invest. 88: 643-655.
17. 146 → Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J. Clin. Invest. 72: 1288-1297.
18. 146 → Gln) variant results in a dominant mode of inheritance. J. Lipid. Res. 31: 45-53.
19. Havel, R. J., L. Kotite, J. P. Kane, P. Tun, and T. Bersot. 1983. Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. J. Clin. Invest 72: 379-387.
20. Rall, S. C., Jr., Y. M. Newhouse, H. R. G. Clarke, K. H. Weisgraber, B. J. McCarthy, R. W. Mahley, and T. P. Bersot. 1989. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. J. Clin. Invest. 83: 1095-1101.
21. Horie, Y., S. Fazio, J. R. Westerlund, K. H. Weisgraber, and S. C. Rall, Jr. 1992. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J. Biol. Chem. 267: 1962-1968.
22. 145 → Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. J. Biol. Chem. 266: 10479-10484.
23. 145 → Cys) is associated with incomplete dominance of type III hyperlipoproteinemia. J. Biol. Chem. 267: 13642-13646.
24. Rall, S. C., Jr., K. H. Weisgraber, T. L. Innerarity, and R. W. Mahley. 1982. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc. Natl. Acad. Sci. USA. 79: 4696-4700.
25. Mann, W. A., R. E. Gregg, D. L. Sprecher, and H. B. Brewer, Jr. 1989. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochim. Biophys. Acta. 1005: 239-244.
26. 146 → Glu) with type III hyperlipoproteinemia. Biochim. Biophys. Acta. 1128: 58-64.
27. 147 → Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinemia. Atherosclerosis. 124: 183-189.
28. Weisgraber, K. H., S. C. Rall, Jr., R. W. Mahley, R. W. Milne, Y. L. Marcel, and J. T. Sparrow. 1986. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J. Biol. Chem. 261: 2068-2076.
29. Mann, W. A., N. Meyer, W. Weber, S. Meyer, H. Greten, and U. Beisiegel. 1995. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J. Lipid. Res. 36: 517-525.
30. Mahley, R. W. 1996. Heparan sulfate proteogiycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Isr. J. Med. Sci. 32: 414-429.
31. Ji, Z-S., S. Fazio, and R. W. Mahley. 1994. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269: 13421-13428.
32. Wardell, M. R., S. O. Brennan, E. D. Janus, R. Fraser, and R. W. Carrel. 1987. Apolipoprotein E2-Christchurch (136 Arg → Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J. Clin. Invest. 80: 483-490.
33. 136 → His): association with mild dyslipidemia and double pre-β very low density lipoproteins. J. Lipid. Res. 36: 57-66.
34. Walden, C. C., M. W. Huff, L. A. Leiter, P. W. Connelly, and R. A. Hegele. 1994. Detection of a new apolipoprotein-E mutation in type III hyperlipoproteinemia using deoxyribonucleic acid restriction typing. J. Clin. Endocrinol. Metab. 78: 699-704.
35. 136 → Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia. Eur J. Clin. Invest. 26: 13-23.
36. 136 → Ser) variant in multigenerational pedigree studies. Atherosclerosis. 122: 33-46.
37. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest 34: 1345-1353.
38. Lindgren, F. T. 1975. Preparative ultracentrifuge laboratory procedures and suggestions for lipoprotein analysis. In Analysis of Lipids and Lipoproteins. E. G. Perkins, editor. Am. Oil Chem. Soc., Champaign, IL. 204-224.
39. Wanner, C., W. H. Hörl, C. H. Luley, and H. Wieland. 1991. Effect of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int. 31: 754-759.
40. Nauck, M., and H. Wieland. 1993. Measurement of lipoprotein cholesterol with the cholesterol dehydrogenase method after electrophoretic lipoprotein separation. A comparison with quantitative lipoprotein electrophoresis and the ultracentrifugation method. Clin. Lab. 39: 757-765.
41. Winkler, K., M. Nauck, R. Siekmeier, W. März, and H. Wieland. 1995. Determination of triglycerides in lipoproteins separated by agarose gel electrophoresis. J. Lipid. Res. 36: 1839-1847.
42. März, W., S. Cezanne, and W. Gross. 1991. Immunoblotting of apolipoprotein E in immobilized pH gradients. Electrophoresis. 12: 59-63.
43. Hixson, J. E., and D. T. Vernier. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid. Res. 31: 545-548.
44. Emi, M., L. L. Wu, M. A. Robertson, R. L. Myers, R. A. Hegele, R. R. Williams, R. White, and J-M. Lalouel. 1988. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics. 3: 373-379.
45. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74: 5463-5467.
46. Gretch, D. G., S. L. Sturley, P. D. Friesen, N. E. Beckage, and A. D. Attie. 1991. Baculovirus-mediated expression of human apolipoprotein E in Manduca sexta larvae generates particles that bind to the low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 88: 8530-8533.
47. O'Reilly, D. R., L. K. Müller, and V. A. Luckow. 1992. Baculovirus Expression Vectors-a Laboratory Manual. W. H. Freeman and Company, New York.
48. Innerarity, T. L., R. E. Pitas, and R. W. Mahley. 1979. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J. Biol. Chem. 254: 4186-4190.
49. Pitas, R. E., T. L. Innerarity, and R. W. Mahley. 1980. Cell surface receptor binding of phospholipid-protein complexes containing different ratios of receptor-active and inactive E apoprotein. J. Biol. Chem. 255: 5454-5460.
50. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
51. Goldstein, J. L., and M. S. Brown. 1974. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with hoinozygous familial hypercholesterolemia. J. Biol. Chem. 249:5153-5162.
52. Goldstein, J. L., S. K. Basu, and M. S. Brown. 1983. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98:241-260.
53. März, W., M. W. Baumstark, H. Scharnagl, V. Ruzicka, S. Buxbaum, J. Herwig, T. Pohl, A. Russ, L. Schaaf, A. Berg, H-J. Böhles, K. H. Usadel, and W. Gross. 1993. Accumulation of 'small dense' low density lipoproteins in a homozygous patient with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL-subfractions with the LDL receptor. J. Clin. Invest. 92: 2922-2933.
54. Feussner, G., J. Dobmeyer, H. J. Gröne, S. Lohmer, and S. Wohlfeil. 1996. A 10-bp deletion in the apolipoprotein ∈ gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia. Am. J. Hum. Genet. 58: 281-291.
55. Yang, Y. W., L. Chan, and W. H. Li. 1991. Cloning and sequencing of bovine apolipoprotein E complementary DNA and molecular evolution of apolipoprotein E, C-I, and C-II. J. Mol. Evol. 32: 469-475.
56. Aggerbeck, L. P., J. R. Wetterau, K. H. Weisgraber, R. W. Mahley, and D. A, Agard. 1988. Crystallization and preliminary X-ray diffraction studies on the amino-terminal (receptor-binding) domain of human apolipoprotein E3 from serum very low density lipoproteins. J. Mol. Biol. 202: 179-181.
57. Dong, L. M., S. Parkin, S. D. Trakhanov, B. Rupp, T. Simmons, K. S. Arnold, Y. M. Newhouse, T. L. Innerarity, and K. H. Weisgraber. 1996. Novel mechanism for defective binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat. Struct. Biol. 3: 718-722.
58. Ji, Z-S., W. J. Brecht, R. D. Miranda, M. M. Hussain, T. L. Innerarity, and R. W. Mahley. 1993. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268: 10160-10167.
59. Ji, Z-S., S. Fazio, Y-L. Lee, and R. W. Mahley. 1994. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J. Biol. Chem. 269: 2764-2772.